ALB and cancer: The data summarized above are consistent with our findings, showing that low-baseline albumin was more common among cancer patients who did not survive at the cut-off date of the NUTRIONCO database (72.4%, Table 5), with a statistically significant association with the outcome, “patient’s death” (p < 0.0001).